Neurodegeneration is one of the biggest areas of unmet medical need in human health. The numbers around Alzheimer’s disease (AD) alone are sobering – a growing epidemic, in part driven by the very healthcare advances that have extended human life. Global dementia cases are projected to almost triple by 2050, rising from 57 million in 2019 to over 150 million. We are living longer, but not always better.

There is no shortage of clinical activity in neurodegeneration but, for simplicity, we will focus on AD in this article. There are around 70 new chemical or biological entities currently in clinical trials for AD, excluding repurposing opportunities and those which could be classed as symptomatic rather than disease-modifying.

By that measure, ambition is not lacking. However, if you look at the underlying data, some troubling patterns begin to emerge in the quest to deliver meaningful therapies for patients.

To read more on about Scripta's solutions to this grand challenge, head to our blog here.